Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
- 1 August 1993
- journal article
- Published by Elsevier in International Journal of Gynecologic Cancer
- Vol. 3 (5) , 299-303
- https://doi.org/10.1046/j.1525-1438.1993.03050299.x
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Epithelial ovarian tumors of borderline malignancyGynecologic Oncology, 1990
- The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreductionAmerican Journal of Obstetrics and Gynecology, 1990
- Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase in patients with ovarian carcinoma: Influence of histological type, grade of differentiation, and clinical stage of diseaseGynecologic Oncology, 1990
- Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: Relevance for differential diagnosisGynecologic Oncology, 1990
- Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovaryGynecologic Oncology, 1990
- Predictive value of CA 125 during early chemotherapy of advanced ovarian cancerGynecologic Oncology, 1990
- CA 125 in the diagnosis of pelvic massesEuropean Journal of Cancer and Clinical Oncology, 1989
- Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancerInternational Journal of Cancer, 1988
- The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancerAmerican Journal of Obstetrics and Gynecology, 1986
- Reporting results of cancer treatmentCancer, 1981